- Home
- AQST vs CELC Comparison
AQST vs CELC Comparison
Compare AQST & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- CELC
- Stock Information
- Founded
- AQST 2004
- CELC 2011
- Country
- AQST United States
- CELC United States
- Employees
- AQST N/A
- CELC N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- AQST Health Care
- CELC Health Care
- Exchange
- AQST Nasdaq
- CELC Nasdaq
- Market Cap
- AQST 390.4M
- CELC 440.0M
- IPO Year
- AQST 2018
- CELC 2017
- Fundamental
- Price
- AQST $5.18
- CELC $54.47
- Analyst Decision
- AQST Strong Buy
- CELC Strong Buy
- Analyst Count
- AQST 7
- CELC 5
- Target Price
- AQST $10.29
- CELC $53.60
- AVG Volume (30 Days)
- AQST 2.4M
- CELC 862.3K
- Earning Date
- AQST 11-03-2025
- CELC 11-13-2025
- Dividend Yield
- AQST N/A
- CELC N/A
- EPS Growth
- AQST N/A
- CELC N/A
- EPS
- AQST N/A
- CELC N/A
- Revenue
- AQST $44,132,000.00
- CELC N/A
- Revenue This Year
- AQST N/A
- CELC N/A
- Revenue Next Year
- AQST $38.71
- CELC N/A
- P/E Ratio
- AQST N/A
- CELC N/A
- Revenue Growth
- AQST N/A
- CELC N/A
- 52 Week Low
- AQST $2.12
- CELC $7.58
- 52 Week High
- AQST $5.80
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- AQST 68.04
- CELC 59.21
- Support Level
- AQST $4.75
- CELC $50.44
- Resistance Level
- AQST $5.27
- CELC $63.06
- Average True Range (ATR)
- AQST 0.30
- CELC 3.03
- MACD
- AQST 0.09
- CELC -0.90
- Stochastic Oscillator
- AQST 75.40
- CELC 44.24
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.